Is Compounded Semaglutide Tested for Purity? How 503A Pharmacies Verify Quality

Is compounded semaglutide tested for purity? Yes, when it comes from a licensed 503A compounding pharmacy: state-licensed pharmacies are required to follow USP compounding standards that include potency, sterility, and identity testing before a preparation is dispensed.

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting, stopping, or changing any medication.*

*Compounded semaglutide and tirzepatide are not FDA-approved. They are not equivalent to brand-name medications. Prescriva is a Management Services Organization (MSO). Clinical services are provided by independently licensed providers in our partner network.*

---

If you have seen news coverage about counterfeit or contaminated GLP-1 products, it is a reasonable thing to want answered before you trust a medication you inject into your own body: how do you know what is actually in the vial?

That question has a real answer, and it is grounded in pharmacy law and testing standards, not marketing reassurance. This article explains exactly what purity and potency testing means for compounded semaglutide, what USP standards require of the pharmacies that prepare it, and what questions you can ask to verify a provider is doing this correctly.

---

Why Purity and Potency Testing Matters

Counterfeit and unregulated GLP-1 products are a documented problem, separate from the question of legitimate compounding. A 2024 study in the *Journal of Medical Internet Research* that purchased and tested semaglutide products sold online without a prescription found significant quality and safety issues across the products evaluated, including labeling and sourcing red flags consistent with counterfeit or substandard manufacturing (Ashraf et al., PMID [39509151](https://pubmed.ncbi.nlm.nih.gov/39509151/)). A related 2024 analysis published in *JAMA Network Open* assessed the safety risks of these same no-prescription online purchases and found meaningful gaps between what these sellers claimed and what a legitimate, prescription-based supply chain provides (Ashraf et al., PMID [39093567](https://pubmed.ncbi.nlm.nih.gov/39093567/)).

These findings are not about licensed, prescription-based 503A compounding pharmacies specifically. They are about the unregulated market that exists alongside it, and they explain why the question "is this actually tested?" is worth asking of any source, licensed or not.

There is a separate, more mundane risk worth understanding too: preparation and dosing errors. A case series published in the *Journal of the American Pharmacists Association* documented poison control center reports involving compounded semaglutide, including instances where patients received or self-administered doses far outside the intended range (Lambson et al., PMID [37392810](https://pubmed.ncbi.nlm.nih.gov/37392810/)). This underscores why potency testing (confirming a preparation actually contains the labeled concentration) and clear labeling both matter as much as sterility.

Purity and potency testing exists to answer two separate questions: is the active ingredient present at the labeled strength, and is the preparation free of contaminants that could cause harm. Both matter, and legitimate 503A pharmacies are required to address both.

---

What USP Standards Require of Compounding Pharmacies

Compounding pharmacies do not operate in a regulatory vacuum. The United States Pharmacopeia (USP) publishes enforceable quality standards that state pharmacy boards use to license and inspect compounding pharmacies, and these standards are the actual mechanism behind the phrase "tested for purity."

USP General Chapter <795> governs nonsterile compounding: pharmaceutical-grade ingredients, proper equipment, documentation of the compounding process, and quality control checks appropriate to the preparation type.

USP General Chapter <797> governs sterile compounding, which applies to injectable medications like compounded semaglutide. This chapter sets requirements for cleanroom conditions, personnel training and competency testing, environmental monitoring, and, critically, testing of the finished preparation before it reaches a patient. Pharmacy practice literature describes USP <797> as establishing the practice standard that separates sterile compounding done safely from sterile compounding done carelessly, precisely because injectable medications bypass the body's natural barriers to contamination (Kastango & Bradshaw, PMID [15487884](https://pubmed.ncbi.nlm.nih.gov/15487884/); Kastango, PMID [15947127](https://pubmed.ncbi.nlm.nih.gov/15947127/)).

State pharmacy boards license and inspect compounding pharmacies against these standards. A 503A pharmacy operating without a valid state compounding license, or one that has had that license suspended for a USP violation, is not a pharmacy any legitimate provider should be sourcing from.

---

What Potency Testing Actually Looks For

Potency testing answers a specific question: does this preparation contain the labeled amount of active ingredient, no more and no less?

For a compounded semaglutide preparation, this means an analytical method (commonly high-performance liquid chromatography, or HPLC) is used to measure the actual semaglutide concentration in a sample from the batch. If the tested concentration falls outside an acceptable range of the labeled strength, that batch does not meet specification and should not be dispensed.

This matters for two reasons. Underdosing means you are not receiving the treatment your provider prescribed, which affects how well the medication works. Overdosing increases the risk and severity of side effects, and in some cases could pose a safety concern. A pharmacy that performs potency testing and can produce a Certificate of Analysis (CoA) for a batch is demonstrating, with data, that the preparation matches the label.

---

What Sterility Testing Actually Looks For

Because compounded semaglutide is injected, it must be free of microbial contamination. Sterility testing under USP <797> addresses this directly, and it typically includes two distinct checks.

Microbial contamination screening verifies that the preparation contains no bacteria, fungi, or other microorganisms that could cause infection at the injection site or systemically.

Endotoxin testing screens for bacterial endotoxins, byproducts of certain bacteria that can trigger a serious immune reaction even after the bacteria themselves are no longer present or viable. This is a standard, non-negotiable test for any compounded sterile injectable.

Environmental monitoring in the compounding facility itself (air quality, surface sampling, personnel technique) is also part of USP <797>'s sterility framework, because the goal is to prevent contamination from occurring in the first place, not just to catch it after the fact.

---

503A vs. 503B: A Quick Clarification

You may see the terms 503A and 503B used, sometimes interchangeably, when providers discuss compounding. They are not the same, and the distinction matters for what testing standard applies.

503A pharmacies are state-licensed compounding pharmacies that prepare medications for individual patients based on a specific prescription. They operate under state pharmacy board oversight and are required to follow USP <795> and <797> standards. They are not FDA-registered facilities and are not required to meet Current Good Manufacturing Practice (cGMP) certification, the standard applied to drug manufacturers.

503B outsourcing facilities are FDA-registered facilities that compound in bulk, without individual patient-specific prescriptions, and are subject to cGMP requirements and direct FDA inspection.

Prescriva sources compounded semaglutide and tirzepatide through 503A-licensed compounding pharmacies. Every prescription is prepared for an individual patient following a clinician review, under USP compounding standards and state pharmacy board oversight. This is a different regulatory pathway than cGMP-certified manufacturing, and no legitimate 503A pharmacy or provider should claim otherwise.

---

Questions to Ask Your Provider About Testing

You do not have to take quality claims on faith. Here is what to ask.

Does your pharmacy hold an active state compounding license? A legitimate provider can name the pharmacy and confirm its license status. Vague answers about "licensed partners" without specifics are worth pushing back on.

Does the pharmacy follow USP <795> and <797> standards? For an injectable like compounded semaglutide, USP <797> compliance is the relevant sterile compounding standard.

Can I see a Certificate of Analysis? A CoA documents that a specific batch was tested for potency, and confirms the results met specification. Not every pharmacy provides this proactively, but a legitimate one should be able to produce it on request.

How is the preparation labeled? Your medication should be labeled with the drug name, strength, lot number, expiration date, storage conditions, and the dispensing pharmacy's information. Missing or vague labeling is a red flag independent of any testing question.

---

Frequently Asked Questions

Is compounded semaglutide tested for purity? Compounded semaglutide from a licensed 503A pharmacy is prepared under USP <795> and <797> standards, which require potency, identity, and sterility testing appropriate to the preparation. This is different from FDA drug approval, but it is a real, enforceable quality framework, not an honor system.

Do 503A pharmacies have cGMP certification? No. cGMP (Current Good Manufacturing Practice) certification applies to FDA-registered 503B outsourcing facilities and drug manufacturers, not to 503A compounding pharmacies. 503A pharmacies are regulated by state pharmacy boards under USP compounding standards. Any pharmacy or provider claiming cGMP certification for a 503A preparation is describing something inaccurately.

What is the difference between potency testing and sterility testing? Potency testing confirms the preparation contains the labeled concentration of active ingredient. Sterility testing confirms the preparation is free of microbial contamination and bacterial endotoxins. Both are part of USP <797> requirements for sterile injectable compounding, and they answer different questions about quality.

How can I verify my pharmacy is actually doing this testing? Ask your provider to name the compounding pharmacy and confirm its active state license. You can independently verify a pharmacy's license status through your state board of pharmacy. Ask whether a Certificate of Analysis is available for your prescription's batch.

Are counterfeit GLP-1 products a real risk? Yes. Independent research analyzing semaglutide products sold online without a prescription has found significant quality and safety issues among those products (PMID [39509151](https://pubmed.ncbi.nlm.nih.gov/39509151/); PMID [39093567](https://pubmed.ncbi.nlm.nih.gov/39093567/)). This risk is associated with unregulated, no-prescription sources, which is a different category from a licensed 503A pharmacy dispensing under a valid prescription. It is one more reason why sourcing and prescription requirements matter, not a reason to avoid legitimate compounding altogether.

---

Making Sense of It

Purity and potency testing is not an abstract regulatory concept. It is the difference between a preparation that matches its label and one that does not, and between an injectable that is sterile and one that carries contamination risk. USP <795> and <797> standards, enforced by state pharmacy boards, are the actual mechanism that makes this testing happen at a licensed 503A pharmacy.

If you want to go deeper on evaluating a provider more broadly, including pharmacy licensing, clinician review, and pricing transparency, see our guide on [how to evaluate a compounded GLP-1 provider](/resources/how-to-evaluate-compounded-glp1-provider-503a-pharmacy). For a broader look at safety, including clinical data on semaglutide itself, see [is compounded semaglutide safe](/resources/is-compounded-semaglutide-safe). For the current regulatory landscape affecting compounded GLP-1s, see [compounded semaglutide regulations in 2026](/resources/compounded-semaglutide-regulations-2026).

Ask questions. Ask for documentation. A provider that cannot answer where your medication comes from and how it is tested is a provider worth reconsidering.

*This content is for educational purposes only and does not constitute medical advice. Compounded GLP-1 medications are not FDA-approved and are not equivalent to brand-name products. Results vary. Consult your healthcare provider before starting any medication.*

*Clinical services are provided by independently licensed providers in Prescriva's partner network. Prescriva (Prescriva LLC) is a Management Services Organization and does not practice medicine.*

---

Sources:

1. Ashraf AR, Mackey TK, Vida RG, Kulcsár G. "Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study." *Journal of Medical Internet Research.* 2024. PMID: [39509151](https://pubmed.ncbi.nlm.nih.gov/39509151/)
2. Ashraf AR, Mackey TK, Schmidt J, Kulcsár G. "Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases." *JAMA Network Open.* 2024. PMID: [39093567](https://pubmed.ncbi.nlm.nih.gov/39093567/)
3. Lambson JE, Flegal SC, Johnson AR. "Administration errors of compounded semaglutide reported to a poison control center-Case series." *Journal of the American Pharmacists Association.* 2023. PMID: [37392810](https://pubmed.ncbi.nlm.nih.gov/37392810/)
4. Kastango ES, Bradshaw BD. "USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy." *American Journal of Health-System Pharmacy.* 2004. PMID: [15487884](https://pubmed.ncbi.nlm.nih.gov/15487884/)
5. Kastango ES. "Blueprint for implementing USP chapter 797 for compounding sterile preparations." *American Journal of Health-System Pharmacy.* 2005. PMID: [15947127](https://pubmed.ncbi.nlm.nih.gov/15947127/)